Treat the Blood
Treat
the
Skin.
Treat
the
Blood.
Patient presentation may
vary based on stage of
disease or severity.
Treat
the
Skin.
Patient presentation may vary based
on stage of disease or severity.
POTELIGEO, a targeted immunotherapy to treat Mycosis Fungoides or Sézary Syndrome,
subtypes of cutaneous T-cell lymphoma (CTCL), who have relapsed or are refractory after at least one prior systemic therapy
1
Mycosis Fungoides may be indolent with skin-only symptoms. About 1 in 3 patients with Mycosis
Fungoides may experience progression within skin or to other compartments, including blood, lymph nodes,
and viscera. Involvement of multiple disease compartments is associated with poor prognosis.2-4
Choose the efficacy and durability of POTELIGEO against Mycosis Fungoides and Sézary Syndrome1
See efficacy data
POTELIGEO has
a
consistent
safety profile
Help eligible patients
access
POTELIGEO
and receive support
Stay connected for updates
and new
POTELIGEO
resource materials
- POTELIGEO [package insert]. Kyowa Kirin Inc., Princeton, NJ USA.
- Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-4739.
- Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018;93(4):546-552.
- Scarisbrick JJ, Hodak E, Bagot M, et al. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;93:47-56.